• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Prevention of Diabetes Macrovascular Complications and Heart Failure
Cardiovascular (CV) mortality in diabetes has declined substantially over the last 3  decades in high-income countries from a multifactorial approach targeting glucose, cholesterol, and blood pressure, and lower smoking rates. Additional CV gains may be achieved from large-scale weight loss, which ongoing trials are testing, and from delaying diabetes in those at highest risk. Fina lly, recent outcome trials support a role for (1) sodium/glucose cotransporter-2 inhibitors, which lower major adverse cardiovascular events but incident heart failure more strongly, and (2) glucagon-like peptide-1 receptor agonists, which lowe...
Source: Endocrinology and Metabolism Clinics of North America - July 12, 2021 Category: Endocrinology Authors: Naveed Sattar Source Type: research

Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users
ConclusionsThis study provides evidence of increased CVD risk associated with hypoglycaemia, especially serious hypoglycaemia events. While associations were attenuated with non‐serious hypoglycaemia, the results were suggestive of a potential increased risk.
Source: Diabetes, Obesity and Metabolism - May 1, 2017 Category: Endocrinology Authors: Anthony P. Nunes, Kristy Iglay, Larry Radican, Samuel S. Engel, Jing Yang, Michael C. Doherty, David D. Dore Tags: ORIGINAL ARTICLE Source Type: research

Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial
We examined whether the incidence of cardiovascular disease in Look AHEAD varied by changes in weight or fitness. Methods Look AHEAD was a randomised clinical trial done at 16 clinical sites in the USA, recruiting patients from Aug 22, 2001, to April 30, 2004. In the trial, 5145 overweight or obese adults aged 45–76 years with type 2 diabetes were assigned (1:1) to an intensive lifestyle intervention or diabetes support and education. In this observational, post-hoc analysis, we examined the association of magnitude of weight loss and fitness change over the first year with incidence of cardiovascular disease. The primar...
Source: The Lancet Diabetes and Endocrinology - August 30, 2016 Category: Endocrinology Source Type: research

Diabetes mellitus related biomarker: the predictive role of growth-differentiation factor-15
Publication date: Available online 9 October 2015 Source:Diabetes & Metabolic Syndrome: Clinical Research & Reviews Author(s): Alexander E. Berezin Growth differentiation factor-15 (GDF-15) is a stress-responsive cytokine, which belongs to super family of the transforming growth factor beta. GDF-15 is widely presented in the various cells (macrophages, vascular smooth muscle cells, adipocytes, cardiomyocytes, endothelial cells, fibroblasts), tissues (adipose tissue, vessels, tissues of central and peripheral nervous system) and organs (heart, brain, liver, placenta) and it plays an important role in the ...
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - October 10, 2015 Category: Endocrinology Source Type: research